Skip to content
DataLookout
Menu

ASCENTNCT06129240

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

StatusActive, Not Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 22 words Show 4 more changesShow less
    • Primary endpoints: details revised at 2 of 2 entries
    • Enrollment closed, study ongoing
    • Trial sites reduced: 23 → 18 locations
    • Study description revised
  2. Notable Trial status changed: Active, Not Recruiting → Recruiting
    • Trial sites expanded: 18 → 23 locations
    v7
  3. Notable Primary completion date: Jul 30, 2026 to Jul 31, 2027v6 Show 9 more changesShow less
    • Eligibility criteria shortened, about 600 words
    • Primary endpoints: 1 to 2
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: 60 to 80
    • Study sites: 23 to 18
    • Study completion date: Oct 31, 2026 to Feb 8, 2028
    • Interventions: LIQ861 (Combination Product) to LIQ861 (Drug)
    • Study description shortened, about 49 words
    • Study arms: 1 to 2
  4. Minor Study sites: 14 to 23v5
  5. Minor Study sites: 8 to 14v4
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Study sites: 3 to 8v3
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 1, 2023 to Dec 28, 2023
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Cohort A: Incident of treatment-emergent drug/device-related adverse events and Serious Adverse Events (SAEs)
Timeframe: Baseline until the end of the study.
Cohort B: Number of participants with treatment-emergent drug/device-related adverse events and Serious Adverse Events (SAEs)
Timeframe: 16 weeks

Arms and interventions

Cohort A

PH-ILD

Cohort B

PH-ILD

Drugs: LIQ861

Sites

18 sites in 1 country